Net Loss [USD, thousands]

Reduction in Carrying Amount of ROU Assets, Operating [USD, thousands]

Reduction in Carrying Amount of ROU Assets, Finance [USD, thousands]

Stock Based Compensation Expense [USD, thousands]

Depreciation and Amortization Expense [USD, thousands]

Change in Fair Value of Convertible SAFE Note Liability [USD, thousands]

Accretion of Discount on Investments [USD, thousands]

Net Cash Used in Operating Activities [USD, thousands]

Purchase of Internal Use Software [USD, thousands]

Purchase of Property and Equipment [USD, thousands]

Purchases of Investments [USD, thousands]

Net Cash Used in Investing Activities [USD, thousands]

Proceeds from Exercise of Stock Options [USD, thousands]

Payments on Finance Leases [USD, thousands]

Treasury Stock Repurchases [USD, thousands]

Payments of Issuance Costs on Convertible SAFE Note [USD, thousands]

Proceeds from Issuance of Convertible SAFE Note [USD, thousands]

Proceeds from Issuance of Common Stock Upon Private Placement Offering, Net of Commissions and Offering Costs [USD, thousands]

Proceeds from Issuance of Common Stock Upon Initial Public Offering, Net of Underwriters' Discounts, Commissions and Other Offering Costs [USD, thousands]

Net Cash Provided by Financing Activities [USD, thousands]

Net Change in Cash, Cash Equivalents and Restricted Cash [USD, thousands]

Interest Paid [USD, thousands]

Prepaid Expenses and Other Current Assets [USD, thousands]

Accounts Payable [USD, thousands]

Accrued Expenses and Other Current Liabilities [USD, thousands]

Lease Liabilities, Operating [USD, thousands]

Lease Liabilities, Finance [USD, thousands]

Cash, Cash Equivalents and Restricted Cash at Beginning of Period [USD, thousands]

Cash, Cash Equivalents and Restricted Cash at End of Period [USD, thousands]

4e23c8c57bd7bd414b79429b241dc55e7b5f357ded0ce42c2d2c364956d05a40

Research and Development Expense [USD, thousands]

General and Administrative Expense [USD, thousands]

Total Operating Expenses [USD, thousands]

Operating Loss [USD, thousands]

Loss on Fair Value Adjustment to Convertible SAFE Note [USD, thousands]

Other Income (Expense), Net [USD, thousands]

Interest Expense [USD, thousands]

Interest Income [USD, thousands]

Total Other Income and Expense [USD, thousands]

Loss from Operations Before Income Taxes [USD, thousands]

Income Taxes [USD, thousands]

Net Unrealized Loss on Investments [USD, thousands]

Total Other Comprehensive Loss [USD, thousands]

Comprehensive Loss [USD, thousands]

Net Loss per Common Share, Basic and Diluted [USD]

Weighted Average Number of Shares Outstanding Used in Computation of Net Loss per Common Share, Basic and Diluted [Shares]

22b3a27d7d899e0195a343f48a520a0743a151272b0156343f1df97808b20c4c

Cash and Cash Equivalents (USD, thousands)

Current Investments (USD, thousands)

Prepaid Expenses and Other Current Assets (USD, thousands)

Total Current Assets (USD, thousands)

Restricted Cash (USD, thousands)

Non-current Investments (USD, thousands)

Property, Plant, and Equipment, Net (USD, thousands)

Finance Lease Right-of-Use Assets, Net (USD, thousands)

Operating Lease Right-of-Use Assets, Net (USD, thousands)

Total Assets (USD, thousands)

Accounts Payable (USD, thousands)

Accrued Expenses and Other Current Liabilities (USD, thousands)

Current Finance Lease Liabilities (USD, thousands)

Current Operating Lease Liabilities (USD, thousands)

Total Current Liabilities (USD, thousands)

Non-current Finance Lease Liabilities (USD, thousands)

Non-current Operating Lease Liabilities (USD, thousands)

Total Liabilities (USD, thousands)

Common Stock (USD, thousands)

Treasury Stock, at Cost (USD, thousands)

Additional Paid-In Capital (USD, thousands)

Accumulated Other Comprehensive Loss (USD, thousands)

Accumulated Deficit (USD, thousands)

Total Shareholders' Equity (USD, thousands)

Total Liabilities and Shareholders' Equity (USD, thousands)

Accrued Bonuses (USD, thousands)

4840d55648b5eea5aa2fe66dc768598bdbcb45eaf459a786223cd1a99b354b85

Number of treated participants across LX2006 studies (participants)

Number of participants in LX2006 studies with at least 6-month follow-up (participants)

Number of patients with an increase in frataxin protein expression (patients)

Total participants enrolled in LX2020 Phase 1/2 trial (participants)

Participants enrolled in LX2020 Phase 1/2 trial, cohort 1 (participants)

Participants enrolled in LX2020 Phase 1/2 trial, cohort 2 (participants)

Percentage increase in PKP2 protein expression for participant 1 in LX2020 trial (percentage)

Percentage increase in PKP2 protein expression for participant 2 in LX2020 trial (percentage)

Percentage reduction in PVCs from baseline for the first LX2020 participant at 6 months (percentage)

ce33054613b01f20700980b4cc7f0aa073fd28c2f432dcd9843e0aa960dc170e

Lexeo Therapeutics Inc (LXEO)

Financials